Roche(ROG VX) – FY sales 42.041bn (vs cons 41.599bn) / EBIT 11.73bn (vs cons 11.86bn) / net profit 9.171bn (vs cons 8.122bn) /Dividend CHF 3.40 (vs 2.50) Outlook: growth guidance for 2007 unchanged – plans to submit Actemra in '07 US and Europe (BB)

Straumann(STMN SW) – FY sales 599.2m (vs cons 595.5m) / EBIT 175.3m (vs cons 173.7m) / net profit 141.9m (vs cons 137.4m) / Dividend CHF 3.00 (vs 2.50) Outlook: company sees '07 sales growth 17-18% - operating margin 29-30% - sees positive impact from Japan in 2H'07 (BB)

Novartis(NOVN VX) – may receive US' FDA approval for Galvus (diabetes) as early as today – about 7% of Americans have diabetes – world market is expected to be worth USD 25bn by 2011 (vs USD 15bn today) (BB)

Lonza(LONN VX) – to invest EUR 31.5m to expand Czech plant to supply US' Altus Pharmaceutical with special blend of enzymes (higher value projects) (BB)

Serono(SERO VX) – FDA questions Merck Serono's new Rebif formula, delays approval – Merck now holds 72.93% of Merck Serono stock (BB)

LEM Holding(LEHN SW) – 9m sales 133.1m (vs exp 133.3m) / order intake 139m (vs exp 136.8m) / EBIT 16.7m (vs exp 16.7m) / net profit 9.6m (vs exp 9.7m) Outlook: LEM said the company remains well on track to reach full year targets (BB)